Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
DCFirst Claim
Patent Images
1. A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject:
- a first dose of 160 mg of adalimumab administered to the human subject within a day; and
a second dose of 80 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose.
6 Assignments
Litigations
1 Petition
Accused Products
Abstract
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn'"'"'s disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
130 Citations
30 Claims
-
1. A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject:
-
a first dose of 160 mg of adalimumab administered to the human subject within a day; and a second dose of 80 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose. - View Dependent Claims (2, 3, 9, 10, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23)
-
-
4. A multiple-variable dose method for treating idiopathic inflammatory bowel disease in a human subject in need thereof, comprising subcutaneously administering to the human subject:
-
a first dose of 160 mg of adalimumab administered as a set of four injections of 40 mg of adalimumab administered to the human subject within a day; and a second dose of 80 mg of adalimumab administered as a set of two injections of 40 mg of adalimumab administered to the human subject within a day, wherein the second dose is administered two weeks following administration of the first dose. - View Dependent Claims (5, 6, 7, 8, 11, 12, 14, 24, 25, 26, 27, 28, 29, 30)
-
Specification